Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease

Xiaoli HUANG; Lin LIU; Zhongtao YUAN; Le LUO; Shiqi LI; Sanbin WANG

doi:10.16016/j.1000-5404.201906230

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease

更新时间：2026-01-09

- Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease
- Journal of Third Military Medical University Vol. 41, Issue 23, Pages: 2290-2295(2019)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.201906230
  CLC：
- Received：26 June 2019，
  
  Published：25 December 2019
- 稿件说明：
移动端阅览
Xiaoli HUANG, Lin LIU, Zhongtao YUAN, et al. Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease[J]. Journal of Third Military Medical University, 2019, 41(23): 2290-2295.
DOI：

Xiaoli HUANG, Lin LIU, Zhongtao YUAN, et al. Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease[J]. Journal of Third Military Medical University, 2019, 41(23): 2290-2295. DOI： 10.16016/j.1000-5404.201906230.

摘要

Abstract

Objective

To study the clinical efficacy and safety of ruxolitinib in the treatment of chronic graft versus host disease (cGVHD).

Methods

We collected the clinical data of 42 cGVHD patients after receiving allogeneic hematopoietic stem cell transplantation from July 1

2016 to February 1

2019 in our hospital. There were 2 specific treatment regimens. For the patients diagnosed with the skin

mouth

eyes

joints or genital tract involvement

5 mg/d ruxolitinib was given (when the patient weighs less than 25 kg

or ruxolitinib is administered in combination with a potent CYP3A4 inhibitor or fluconazole

the total dose is halved) on the basis of the original immunosuppressant therapy. For those diagnosed with lung

liver or gastrointestinal tract involvement

5 mg/d ruxolitinib and 1 mg/(kg·d) methylprednisolone were given on the basis of the original immunosuppressant therapy. The clinical efficacy was evaluated in 1 and 3 month after treatment. Peripheral blood test

coagulation function

copy number of human cytomegalovirus and chest CT scanning were performed every week.

Results

Among the 42 cGVHD patients

overall response rates (ORR) were 85.7% (36/42) and 95.2% (40/42) at 1 month and 3 months after treatment

respectively. In the process of this study

6 patients developed pulmonary infection

and 4 patients experienced bleeding events. There were 12 patients having human cytomegalovirus and epstein-barr virus infection or the virus copy number being continued to rise. Bone marrow suppression at grade of Ⅰ~Ⅱ presented in 8 patients. During the follow-up period of 4 (1~19) months

no one patient was lost

and 4 patients (9.5%

4/42) died

due to leukemia recurrence

pulmonary infection and poor control of cGVHD.

Conclusion

Ruxolitinib has significant efficacy in the treatment of cGVHD

with low adverse reactions and preventable and tolerable effects.

关键词

Keywords

references

PAVLETIC S Z MARTIN P LEE S J Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. response criteria working group report Biol Blood Marrow Transplant 2006 12 3 252 266 10.1016/j.bbmt.2006.01.008 PAVLETIC S Z, MARTIN P, LEE S J, et al . Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. response criteria working group report[J ] . Biol Blood Marrow Transplant, 2006, 12(3): 252-266. DOI:10.1016/j.bbmt.2006.01.008.

ASSOUAN D LEBON D CHARBONNIER A Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus -host disease Br J Haematol 2018 181 5 687 689 10.1111/bjh.14679 ASSOUAN D, LEBON D, CHARBONNIER A, et al . Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus -host disease[J ] . Br J Haematol, 2018, 181(5): 687-689. DOI:10.1111/bjh.14679.

MARTIN P J STORER B E INAMOTO Y An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease Blood 2017 130 3 360 367 10.1182/blood-2017-03-775767 MARTIN P J, STORER B E, INAMOTO Y, et al . An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease[J ] . Blood, 2017, 130(3): 360-367. DOI:10.1182/blood-2017-03-775767.

JAGLOWSKI S M BLAZAR B R How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD Blood Adv 2018 2 15 2012 2019 10.1182/bloodadvances.2018013060 JAGLOWSKI S M, BLAZAR B R. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD[J]. Blood Adv, 2018, 2(15): 2012-2019. DOI:10.1182/bloodadvances.2018013060.

ZEISER R BLAZAR B R Pathophysiology of chronic graft-versus-host disease and therapeutic targets N Engl J Med 2017 377 26 2565 2579 10.1056/nejmra1703472 ZEISER R, BLAZAR B R. Pathophysiology of chronic graft-versus-host disease and therapeutic targets[J]. N Engl J Med, 2017, 377(26): 2565-2579. DOI:10.1056/nejmra1703472.

IM A HAKIM F T PAVLETIC S Z Novel targets in the treatment of chronic graft-versus-host disease Leukemia 2017 31 3 543 554 10.1038/leu.2016.367 IM A, HAKIM F T, PAVLETIC S Z. Novel targets in the treatment of chronic graft-versus-host disease[J]. Leukemia, 2017, 31(3): 543-554. DOI:10.1038/leu.2016.367.

MASCARENHAS J HOFFMAN R Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis Clin Cancer Res 2012 18 11 3008 3014 10.1158/1078-0432.CCR-11-3145 MASCARENHAS J, HOFFMAN R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis[J]. Clin Cancer Res, 2012, 18(11): 3008-3014. DOI:10.1158/1078-0432.CCR-11-3145.

SPOERL S MATHEW N R BSCHEIDER M Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease Blood 2014 123 24 3832 3842 10.1182/blood-2013-12-543736 SPOERL S, MATHEW N R, BSCHEIDER M, et al . Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease [J ] . Blood, 2014, 123(24): 3832-3842. DOI:10.1182/blood-2013-12-543736.

JAGASIA M ZEISER R ARBUSHITES M Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials Immunotherapy 2018 10 5 391 402 10.2217/imt-2017-0156 JAGASIA M, ZEISER R, ARBUSHITES M, et al . Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials[J ] . Immunotherapy, 2018, 10(5): 391-402. DOI:10.2217/imt-2017-0156.

JAGASIA M H GREINIX H T ARORA M National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report Biol Blood Marrow Transplant 2015 21 3 389 401.e1 10.1016/j.bbmt.2014.12.001 JAGASIA M H, GREINIX H T, ARORA M, et al . National institutes of health consensus developm ent project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report[J ] . Biol Blood Marrow Transplant, 2015, 21(3): 389-401.e1. DOI:10.1016/j.bbmt.2014.12.001.

李小平张曦慢性移植物抗宿主病二线治疗进展中华血液学杂志 2019 40 2 160 163 10.3760/cma.j.issn.0253-2727.2019.02.014 李小平, 张曦.慢性移植物抗宿主病二线治疗进展[J].中华血液学杂志, 2019, 40(2):160-163.DOI:10.3760/cma.j.issn.0253-2727.2019.02.014.

LI X P ZHANG X Progress in second-line treatment of chronic graft-versus-host disease Chin J Hematol 2019 40 2 160 163 10.3760/cma.j.issn.0253-2727.2019.02.014 LI X P, ZHANG X. Progress in second-line treatment of chronic graft-versus-host disease[J]. Chin J Hematol, 2019, 40(2):160-163.DOI:10.3760/cma.j.issn.0253-2727.2019.02.014.

MA H H LU C S ZIEGLER J Absence of Stat1 in donor CD4 + T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice J Clin Invest 2011 121 7 2554 2569 10.1172/JCI43706 MA H H, LU C S, ZIEGLER J, et al . Absence of Stat1 in donor CD4 + T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice[J ] . J Clin Invest, 2011, 121(7): 2554-2569. DOI:10.1172/JCI43706.

MA H H ZIEGLER J LI C L Sequential activation of inflammatory signaling pathways during graft-versus-host disease(GVHD): early role for STAT1 and STAT3 Cell Immunol 2011 268 1 37 46 10.1016/j.cellimm.2011.01.008 MA H H, ZIEGLER J, LI C L, et al . Sequential activation of inflammatory signaling pathways during graft-versus-host disease(GVHD): early role for STAT1 and STAT3[J ] . Cell Immunol, 2011, 268(1): 37-46. DOI:10.1016/j.cellimm.2011.01.008.

BLAZAR B R MURPHY W J ABEDI M Advances in graft-versus-host disease biology and therapy Nat Rev Immunol 2012 12 6 443 458 10.1038/nri3212 BLAZAR B R, MURPHY W J, ABEDI M. Advances in graft-versus-host disease biology and therapy[J]. Nat Rev Immunol, 2012, 12(6): 443-458. DOI:10.1038/nri3212.

HEINE A HELD S A DAECKE S N The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo Blood 2013 122 7 1192 1202 10.1182/blood-2013-03-484642 HEINE A, HELD S A, DAECKE S N, et al . The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo [J ] . Blood, 2013, 122(7): 1192-1202. DOI:10.1182/blood-2013-03-484642.

TAKAHASHI S HASHIMOTO D HAYASE E Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease Blood 2018 131 18 2074 2085 10.1182/blood-2017-06-792614 TAKAHASHI S, HASHIMOTO D, HAYASE E, et al . Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease[J ] . Blood, 2018, 131(18): 2074-2085. DOI:10.1182/blood-2017-06-792614.

CHOI J ZIGA E D RITCHEY J IFNγR signaling mediates alloreactive T-cell trafficking and GVHD Blood 2012 120 19 4093 4103 10.1182/blood-2012-01-403196 CHOI J, ZIGA E D, RITCHEY J, et al . IFNγR signaling mediates alloreactive T-cell trafficking and GVHD[J ] . Blood, 2012, 120(19): 4093-4103. DOI:10.1182/blood-2012-01-403196.

CHOI J COOPER M L ALAHMARI B Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect PLoS ONE 2014 9 10 e109799 10.1371/journal.pone.0109799 CHOI J, COOPER M L, ALAHMARI B, et al . Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect[J ] . PLoS ONE, 2014, 9(10): e109799. DOI:10.1371/journal.pone.0109799.

CARNITI C GIMONDI S VENDRAMIN A Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects Clin Cancer Res 2015 21 16 3740 3749 10.1158/1078-0432.CCR-14-2758 CARNITI C, GIMONDI S, VENDRAMIN A, et al . Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects[J ] . Clin Cancer Res, 2015, 21(16): 3740-3749. DOI:10.1158/1078-0432.CCR-14-2758.

ZHONG J YANG P MUTA K Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock PLoS ONE 2010 5 3 e9593 10.1371/journal.pone.0009593 ZHONG J, YANG P, MUTA K, et al . Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock[J ] . PLoS ONE, 2010, 5(3): e9593. DOI:10.1371/journal.pone.0009593.

ZEISER R BURCHERT A LENGERKE C Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey Leukemia 2015 29 10 2062 2068 10.1038/leu.2015.212 ZEISER R, BURCHERT A, LENGERKE C, et al . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey[J ] . Leukemia, 2015, 29(10): 2062-2068. DOI:10.1038/leu.2015.212.

MORI Y IKEDA K INOMATA T Ruxolitinib treatment for GvHD in patients with myelofibrosis Bone Marrow Transplant 2016 51 12 1584 1587 10.1038/bmt.2016.256 MORI Y, IKEDA K, INOMATA T, et al . Ruxolitinib treatment for GvHD in patients with myelofibrosis[J ] . Bone Marrow Transplant, 2016, 51(12): 1584-1587. DOI:10.1038/bmt.2016.256.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of HCQ versus spironolactone in treatment of IgA nephropathy based on RAASi: a real-world study

Magnetic resonance imaging-based assessment of seromuscular layer injuries early after ultrasound ablation of uterine fibroids

Bone cement-injectable cannulated pedicle screw augmented with polymethylme-thacrylate in osteoporotic spine: a mid- and long-term clinical efficacy of 128 cases

Safety of canagliflozin, empagliflozin and dapagliflozin for T2DM patients: a network meta-analysis

Clinical efficacy of CARTOSound-guided radiofrequency ablation for hypertrophic obstructive cardiomyopathy

Related Author

Jian QIN

Jiachuan XIONG

Jinghong ZHAO

Qing WEI

Jinyun CHEN

Yinuo LIU

Shaojiang MO

Rong ZHANG

Related Institution

Department of Nephrology, Chongqing Key Laboratory for Prevention and Treatment of Chronic Kidney Disease, Chongqing Clinical Research Center of Kidney and Urinary Diseases, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

State Key Laboratory of Ultrasound Engineering in Medicine Co-founded by Chongqing and the Ministry of Science and Technology, Chongqing Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Collaborative Innovation Center for Minimally-invasive and Noninvasive Medicine, College of Biomedical Engineering, Chongqing Medical University

Ultrasound Ablation Center, the First Affiliated Hospital of Chongqing Medical University

Department of Orthopaedics, Center of Orthopaedic Surgery, First Affiliated Hospital of Army Medical University (Third Military Medical University)

School of Pharmacy, Southwest Medical University

⁰